AVTX
NASDAQ HealthcareAvalo Therapeutics, Inc. - Common Stock
Biotechnology
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ร-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ร, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
๐ Market Data
| Price | $13.71 |
|---|---|
| Volume | 720,704 |
| Market Cap | 312.43M |
| Beta | 0.940 |
| RSI (14-Day) | 52.6 |
| 200-Day MA | $14.24 |
| 50-Day MA | $15.21 |
| 52-Week High | $20.72 |
| 52-Week Low | $3.39 |
| Forward P/E | -4.52 |
| Price / Book | 3.06 |
๐ฏ Investment Strategy Scores
AVTX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (63/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (7/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find AVTX in your text
Paste any article, transcript, or post โ the tool will extract AVTX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.